Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
An amendment to this paper has been published and can be accessed via the original article.
Main Authors: | Kimberly Legault, Mark Blostein, Marc Carrier, Susan Kahn, Sam Schulman, Sudeep Shivakumar, Cynthia Wu, Mark A. Crowther |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Pilot and Feasibility Studies |
Online Access: | http://link.springer.com/article/10.1186/s40814-020-00614-0 |
Similar Items
-
A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
by: Kimberly Legault, et al.
Published: (2020-04-01) -
Improvement of Cardiac Vegetations in Antiphospholipid Syndrome with Enoxaparin and Corticosteroids after Rivaroxaban Failure
by: Eric Granowicz, et al.
Published: (2018-01-01) -
Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases
by: Ewa Haładyj, et al.
Published: (2016-07-01) -
Development of intracardiac thrombus in a young patient with antiphospholipid syndrome while she was on rivaroxaban: Case report and literature review
by: Elabbass A. Abdelmahmuod, et al.
Published: (2021-05-01) -
What’s new in VTE risk and prevention in orthopedic surgery
by: Susan R. Kahn, et al.
Published: (2020-03-01)